Products: BC Insulins for Insulinotherapy
Diabetes: global epidemic
The control of glycemia is normally ensured by Insulin. In a diabetic, this process of blood sugar regulation fails for one of those two reasons:
- a lack of insulin production : this is called type 1 diabetes insulin -dependent (10% of diabetics).
- to the ineffectiveness of insulin produced : this is calledtype 2 diabetic insulin-resistant (90% of diabetics).
Glucose concentration must be maintained in a narrow window between 80 and 140 mg / dl., a concentration above 140 mg / dl corresponds to hyperglycemia and can cause serious complications (cardiovascular disease, neuropathy, blindness...) at long term. A concentration below 80 mg / dl corresponds to hypoglycemia, incurring a fatal risk for patients.
A fast growing disease
Diabetes is a major chronic disease affecting many individuals, for which very high growth rates are expected in the coming years. The International Diabetes Federation* estimates that between 2007 and 2025 the number of diabetics in the world are expected to grow over 55% (in the population aged 20-79 years) and to rise from 246 million to 380 million people. If Europe (+ 21%) and North America (+ 43%) expected to experience growth rates below the world average, emerging markets are likely to face an explosion of diabetes (Central America and South America + 102% + 80% Africa, Southeast Asia is + 73 %...).
(*) Diabetes Atlas 3rd edition (2007), International Diabetes Federation
This leads to an increase in the number of diabetics in the same population. In 2030, the percentage of the diabetic population in the United States, Mexico and some countries in the Middle East should be above 12%. Many other countries in Europe, the Mediterranean and Asia will experience these rates of diabetes in their population to be over 9%.
prevalence of diabetes in a population aged between 20 and 79 years by 2030
Sourcebook : Fédération Internationale du Diabète
According to Business Insights1, the treatment of diabetics with insulin has grown by 15% in 2010 to reach more than $17.2B, and represent nearly 53% of the total worldwide market of diabetic products.
115 avenue Lacassagne
69003 Lyon - France
Tel: +33 (0)4 72 610 610
Fax: +33 (0)4 72 36 39 67